Drug Approval | February 23, 2023
Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
This artificial RNA ligase has higher thermostability than natural RNA ligase
In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
There is a fast resurgence in the transplant activities post COVID
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Subscribe To Our Newsletter & Stay Updated
